Form 8-K - Current report:
SEC Accession No. 0000950170-22-015518
Filing Date
2022-08-08
Accepted
2022-08-08 16:07:39
Documents
13
Period of Report
2022-08-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cyt-20220808.htm   iXBRL 8-K 56189
2 EX-99.1 cyt-ex99_1.htm EX-99.1 27850
  Complete submission text file 0000950170-22-015518.txt   211009

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cyt-20220808_pre.xml EX-101.PRE 11354
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cyt-20220808_lab.xml EX-101.LAB 13887
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cyt-20220808.xsd EX-101.SCH 2443
7 EXTRACTED XBRL INSTANCE DOCUMENT cyt-20220808_htm.xml XML 4893
Mailing Address 128 SPRING STREET BUILDING A, SUITE 510 LEXINGTON MA 02421
Business Address 128 SPRING STREET BUILDING A, SUITE 510 LEXINGTON MA 02421 857-285-4140
Cyteir Therapeutics, Inc. (Filer) CIK: 0001662244 (see all company filings)

EIN.: 455429901 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40499 | Film No.: 221144384
SIC: 2834 Pharmaceutical Preparations